17 November 2007
Biocon
Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon offers novel therapies on a platform of affordable innovation.
we would not like to sell the of stock if u remember we recommend at 467 with target of 689 our research shows stock is in its youth now it can either give bonus or can touch more than 800 ans if someone want to enter in nifty he can Stoploss is 5710 on closing basis and Nifty can touch 6435 soon.
by erectusplus at 11:55:00 |
0 Comments:
Post a Comment
<< Home